Back
  1. Home
  2. Profile of Céline Cherdon (ULiège)
Profil

Cherdon Céline

Main Referenced Co-authors
Defraigne, Jean  (11)
de Leval, Laurence  (10)
Drion, Pierre  (10)
Hanson, Julien  (9)
Rolin, Stéphanie (9)
Main Referenced Keywords
atherosclerosis (8); BM-573 (6); thromboxane (4); TP receptor (4); adhesion molecule (2);
Main Referenced Unit & Research Centers
CREDEC (2)
CREDEC et GIGA-R (1)
FUNDP (1)
Giga-ULiège (1)
NTHC (1)
Main Referenced Disciplines
Cardiovascular & respiratory systems (9)
Pharmacy, pharmacology & toxicology (2)
Biochemistry, biophysics & molecular biology (2)
Surgery (1)

Publications (total 13)

The most downloaded
41 downloads
Cherdon, C., Rolin, S., de Leval, L., Drion, P., Defraigne, J.-O., Ooms, A., & Dogné, J.-M. (01 December 2009). The use of an adapted model allows contributing to the “Reduction” of mice used in experimental protocols: the case of the apoE–deficient (apo E-/-) mice in a model of atherosclerosis control [Poster presentation]. Belgian Council for Animal Science Symposium, Blankenberge, Belgium. https://hdl.handle.net/2268/27379

The most cited

18 citations (Scopus®)

Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., Michiels, C., Pirotte, B., Masereel, B., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins and Other Lipid Mediators. doi:10.1016/j.prostaglandins.2011.03.001 https://hdl.handle.net/2268/87430

Cherdon, C. (2011). Étude de molécules brevetées comme agents antiathérosclérotiques dans un modèle murin d’athérosclérose et sur des cellules primaires d’origine humaine [Doctoral thesis, Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/314780

Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., michiels, C., Pirotte, B., Mullier, F., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 INHIBITS THE EARLY ATHEROSCLEROTIC LESIONS IN APO-E DEFICIENT MICE BY BLOCKING TP RECEPTORS AND THROMBOXANE SYNTHASE. In Congress of the International Society of Thrombosis and Hemostasis- 57th Annual SSC Meeting.
Peer reviewed

Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., Michiels, C., Pirotte, B., Masereel, B., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins and Other Lipid Mediators. doi:10.1016/j.prostaglandins.2011.03.001
Peer Reviewed verified by ORBi

Cherdon, C., Rolin, S., de Leval, L., Drion, P., Defraigne, J.-O., Ooms, A., & Dogné, J.-M. (01 December 2009). The use of an adapted model allows contributing to the “Reduction” of mice used in experimental protocols: the case of the apoE–deficient (apo E-/-) mice in a model of atherosclerosis control [Poster presentation]. Belgian Council for Animal Science Symposium, Blankenberge, Belgium.

Cherdon, C., Rolin, S., Ooms, A., de Leval, L., Drion, P., Defraigne, J.-O., & Dogné, J.-M. (2009). Le bm-573, un antagoniste original du récepteur au thromboxane a2, réduit le développement des lésions athéromateuses chez des souris déficientes en apolipoprotéine e (apo e-/-) contrairement a l’aspirine [Paper presentation]. 21ème Journées Franco-Belges de Pharmaco chimie, 28 et 29 mai 2009, , Belgique, Mons, Belgium.
Peer reviewed

Cherdon, C., Rolin, S., de Leval, L., Drion, P., Dogné, J.-M., & Defraigne, J.-O. (2008). Study of thromboxane modulators in a murine model of atherosclerosis [Paper presentation]. PhD Students’ day (Doctoral school of Physiology and Pharmacology), Namur, Belgium.
Peer reviewed

Cherdon, C., Rolin, S., Hanson, J., Drion, P., de Leval, L., Dogné, J.-M., & Defraigne, J.-O. (11 October 2007). Bm-573, an original thromboxane receptor antagonist, reduces development of atherosclerosis in apoe–deficient (apo e-/-) mice [Poster presentation]. Treizième forum des sciences pharamceutiques, Spa, Belgium.

Cherdon, C., Rolin, S., Hanson, J., Drion, P., de Leval, L., Defraigne, J.-O., & Dogné, J.-M. (22 June 2007). Bm-573, a thromboxane receptor antagonist, reduces development of atherosclerosis in apoe–deficient mice [Poster presentation]. FROM CELL TO MAN TO SOCIETY - XIX World Congress of the ISHR, Bologne, Italy.

Cherdon, C., Rolin, S., Hanson, J., Drion, P., de Leval, L., Defraigne, J.-O., & Dogné, J.-M. (10 May 2007). Le bm-573, un antagoniste original de récepteur au thromboxane a2, réduit le développement des lesions atheromateuses chez des souris deficientes en apolipoproteine e (apo e-/-) [Poster presentation]. 21ème Journées Franco-Belges de Pharmaco chimie, , Namur, Belgique, Namur, Belgium.

Cherdon, C., Rolin, S., Hanson, J., Drion, P., De Leval, L., Defraigne, J.-O., & Dogné, J.-M. (2007). BM-573, a thromboxane receptor antagonist, reduces development of atherosclerosis in apoE–deficient mice. Journal of Molecular and Cellular Cardiology, 42 (suppl 1.), 33-34. doi:10.1016/j.yjmcc.2007.03.095
Peer Reviewed verified by ORBi

Rolin, S.* , Hanson, J.* , Vastersaegher, C., Cherdon, C., Pratico, D., Masereel, B., & Dogné, J.-M. (2007). BM-520, an original TXA(2) modulator, inhibits the action of thromboxane A(2) and 8-iso-prostaglandin F-2 alpha in vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents. Prostaglandins and Other Lipid Mediators, 84 (1-2), 14-23. doi:10.1016/j.prostaglandins.2007.03.002
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Cherdon, C., Hanson, J., Pirotte, B., Dogne, J. M., & Defraigne, J.-O. (June 2006). Activité préférentielle de la 8-iso-prostaglandine F2A (8-iso-PGF2A) sur l’isoforme alpha du récepteur au thromboxane A2 [Poster presentation]. 20èmes Journées Franco-Belges de Pharmacochimie, Lille, France.

Cherdon, C., Rolin, S., Hanson, J., Duwez, L., Drion, P., Pincemail, J., de Leval, L., Defraigne, J.-O., & Dogné, J.-M. (17 May 2006). The use of an apoE–deficient (apoE-/-) mice model to characterize the therapeutic benefits of original thromboxane modulators [Poster presentation]. Bioforum 2006, Liège, Belgique, Liège, Belgium.

Contact ORBi